On 18 October 2017, the multi-center clinical investigator meeting of sultamicillin for suspension was successfully held in Suzhou!

Participating in Beijing Children's Hospital, Peking University First Hospital, Shanghai Children's Hospital, West China Second Hospital of Sichuan University, Shenzhen Children's Hospital, Shanxi Children's Hospital, Shengjing Hospital Affiliated to China Medical University, and Jiangxi Children's Hospital,The multi-center clinical investigator meeting of sultamicillin for suspension after marketing was successfully held in Suzhou, and nearly 20 major investigators and project directors from relevant hospitals participated in the meeting.

　　Report on the modified comments and suggestions made by the experts during the previous seminar.

　　Experts are carefully reviewing the plan. 

　　The proposal will be questioned and discussed by President Shen and other experts.

　　Responding to questions posed by experts.

At this meeting, the economic part of the protocol, hematology test, sputum culture, concomitant medication and other issues were analyzed and discussed rigorously, and the relevant details were strictly stipulated at the end.

Finally, Professor Zhao Chengsong pointed out in his summary statement that there are some difficulties in clinical trials of pediatric medicines, so everyone needs to treat them carefully and carefully, and hope that when multi-center clinical trials are really carried out, they can strictly follow the procedures shown in, and the revised protocol is expected to be carefully studied by experts. She said every clinical trial has grown up, and finally thanked you again for coming to this meeting.